Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
521
datasets available to search
ShareScore release 0.9.0
Dataset results
521 results for “Patient survival”
Predicting Survival of Tongue Cancer Patients by Machine Learning Models
<p>This repository contains the dataset used in the paper "Predicting Survival of Tongue Cancer Patients by Machine Learning Models." The dataset contains information on 1712 tongue cancer curative surgery recipients. Each row represents one patient. The meaning of each variable is summarized here:</p> <ul> <li>id: patient identifier</li> <li>gender: patient sex</li> <li>survival: patient survival status at follow-up; 0: survival, 1: death</li> <li>follow_time: length of follow-up period in days</li> <li>part: site of operation</li> <li>stage: tumor stage; 0: very small, no spreading, 1: small, no spreading, 2: some growth, spreading, 3: large, spreading to surrounding tissue or lymph nodes, 4A/4B/4C: larger, metastasis to at least one other organ</li> <li>op: operation status; 1: complete</li> <li>rt: radiation therapy status; 0: not received, 1: received</li> <li>ct: chemotherapy status; 0: not received, 1: received</li> <li>t_stage: tumor size; 1 (small) to 4 (large)</li> <li>n_stage: metastasis to lymph nodes; 0 (no metastasis) to 3 (metastasis to multiple lymph nodes)</li> <li>grade: tumor grade; 1 (no proliferation) to 3 (aggressive proliferation)</li> </ul>
Digitized patient level time to event data of overall survival
<p>This dataset contains digitized patient level time to event data for overall survival of patients with locally advanced and metastatic (stage IIIB/IV) Non-small cell lung cancer (NSCLC). The data can be used to recreate the original Kaplan-Meier survival curves that were published in randomized controlled trials, in order to perform secondary analysis on the survival data. In order to recreate a survival curve, you need two csv.files per trial arm that are in this <br> database: (1) starting with 'surv_', containing the individual patient level time to event data, and (2) starting with 'natrisk_', containing the corresponding numbers at risk table. For the methodology and r-code that can be used for this purpose we refer to article that is linked to this dataset. </p>
Association between Dysregulated Expression of Ca2+ and ROS-Related Gene Pairs and Breast Cancer Patient Survival
<p>This file is composed of two documents:</p> <ul> <li>Supplementary File 1 containing three Excel files with cumulative proportion survival from redox-related genes, calcium-related genes, and redox and calcium-related genes.</li> <li>Supplementary Table 3 including an Excel file with a functional enrichment analysis using redox and calcium correlated genes. Cell cycle regulation (sheet 1) and Cell adhesion and projection (sheet 2) were the biological processes more enriched.</li> </ul> <p>Both supplementary tables belongs to the study <strong>Association between Dysregulated Expression of Ca2+ and ROS-Related Gene Pairs and Breast Cancer Patient Survival</strong>, published in <strong>Molecular Diagnosis and therapy</strong></p>
The Role of Genomic Data in Stratifying Patients within Predictive Models for Breast Cancer Survival Outcome
<p>Data associated with my PhD thesis titled "The Role of Genomic Data in Stratifying Patients within Predictive Models for Breast Cancer Survival Outcome".</p>
HINC dataset from: Homeopathic treatment as an add-on therapy may improve quality of life and prolong survival in patients with non-small cell lung cancer: A prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study
<p class="CxSpFirst"><b>Background:</b> Patients with advanced non-small cell lung cancer (NSCLC) have limited treatment options. Alongside conventional anticancer treatment, additive homeopathy might help to alleviate side effects of conventional therapy. The aim of the present study was to investigate whether additive homeopathy might influence quality of life (QoL) and survival in NSCLC patients.</p> <p class="CxSpMiddle"><b>Methods:</b> In this prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter, phase III study, we evaluated the possible effects of additive homeopathic treatment compared with placebo in NSCLC stage IV patients with respect to QoL in the two randomized groups and survival time in all three groups. Treated patients visited the outpatients' centers every 9 weeks. 150 Patients with stage IV NSCLC were included in the study. 98 received either individualized homeopathic remedies (n=51) or placebo (n=47) in a double-blinded fashion. 52 control patients without any homeopathic treatment were observed for survival only. The constituents of the different homeopathic remedies were mainly of plant, mineral or animal origin. The remedies were manufactured by stepwise dilution and succussion, thereby preparing stable Good Manufacturing Practice grade formulations.</p> <p class="CxSpMiddle"><b>Results:</b> QoL as well as functional and symptom scales showed significant improvement in the homeopathy group when compared with placebo after 9 and 18 weeks of homeopathic treatment (p<0.001). Median survival time was significantly longer in the homeopathy group (435 days) vs placebo (257 days; p=0.010) as well as vs control (228 days; p<0.001). Survival rate in the homeopathy group differed significantly from placebo (p=0.020) and from control (p<0.001).</p> <p class="CxSpMiddle"><b>Conclusion:</b> QoL improved significantly in the homeopathy group compared with placebo. In addition, survival was significantly longer in the homeopathy group versus placebo and control. A higher QoL might have contributed to the prolonged survival. The study suggests that homeopathy positively influences not only QoL but also survival. Further studies including other tumor entities are warranted.</p>
Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening
<p>We uploaded the image of the mansucript <strong>Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening </strong>accepted on Biology.</p>
Validation of Sepsis-3 using survival analysis and clinical evaluation of quick SOFA, SIRS, and burn-specific SIRS for sepsis in burn patients with suspected infection
<p><span><strong>Purpose</strong>: Sepsis-3 is a life-threatening organ dysfunction caused by dysregulated host responses to infection; and defined using the Sepsis-3 criteria, introduced in 2016, however, the criteria need to be validated in specific clinical fields. We investigated mortality prediction and compared the diagnostic performance of quick Sequential Organ Failure Assessment (qSOFA), systemic inflammatory response syndrome (SIRS), and burn-specific SIRS (bSIRS) in burn patients.</span></p> <p><span><strong>Methods</strong>: This single-center retrospective cohort study examined burn patients in Seoul, Korea during January 2010–December 2020. Overall, 1,391 patients with suspected infection were divided into four sepsis groups using SOFA, qSOFA, SIRS, and burn-specific SIRS. </span></p> <p><span><strong>Results</strong>: Hazard ratios (HRs) of all unadjusted models were statistically significant; however, the HR (0.726, p = 0.0080.001) in the SIRS ≥2 group is below 1. In the adjusted model, HRs of the SOFA ≥2 (2.426, p < 0.001), qSOFA ≥2 (7.198, p < 0.001), and SIRS ≥2 (0.575, p < 0.001) groups were significant. The diagnostic performance of dichotomized qSOFA, SIRS, and bSIRS for sepsis was defined by the Sepsis-3 criteria. The mean onset day was 4.13±2.97 according to Sepsis-3. The sensitivity of SIRS (0.989, 95% confidence interval [CI]: 0.982–0.994) was higher than that of qSOFA (0.841, 95% CI: 0.819–0.861) and bSIRS (0.803, 95% CI: 0.779–0.825). Specificities of qSOFA (0.929, 95% CI: 0.876–0.964) and bSIRS (0.922, 95% CI: 0.868–0.959) were higher than those of SIRS (0.461, 95% CI: 0.381–0.543).</span></p> <p><span><strong>Conclusion</strong>: Sepsis-3 is a good alternative diagnostic tool because it reflects sepsis severity without delaying diagnosis. SIRS showed higher sensitivity than qSOFA and bSIRS and may therefore more adequately diagnose sepsis.</span></p>
Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients
<p>Supplementary materials for the article titled “Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients”</p>
Development and Validation of a Deep Learning-Based Survival Prediction Model for Pediatric Glioma Patients: A Retrospective Study Using the SEER Database and Chinese Data
ClinicalTrials.gov study NCT06199388. IPD Sharing: NO. Countries: 1. Publications: 2.
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial
ClinicalTrials.gov study NCT00880087. IPD Sharing: Not stated. Countries: 3. Publications: 10.
Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
ClinicalTrials.gov study NCT07373951. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
ClinicalTrials.gov study NCT04735367. IPD Sharing: NO. Countries: 1. Publications: 2.
Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL
ClinicalTrials.gov study NCT03123887. IPD Sharing: NO. Countries: 1. Publications: 11.
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT01412957. IPD Sharing: Not stated. Countries: 16. Publications: 1.
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itsel
ClinicalTrials.gov study NCT06086340. IPD Sharing: NO. Countries: 1. Publications: 1.
PTSD After ICU Survival - Caring for Patients With Traumatic Stress Sequelae Following Intensive Medical Care
ClinicalTrials.gov study NCT03315390. IPD Sharing: YES. Countries: 1. Publications: 3.
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
ClinicalTrials.gov study NCT00071799. IPD Sharing: Not stated. Countries: 15. Publications: 6.
Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
ClinicalTrials.gov study NCT02947087. IPD Sharing: YES. Countries: 1. Publications: 0.
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial
ClinicalTrials.gov study NCT00878644. IPD Sharing: NO. Countries: 2. Publications: 14.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
ClinicalTrials.gov study NCT00760929. IPD Sharing: YES. Countries: 11. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.